• Tandem Diabetes Care posted second-quarter sales up 6% to USD 254.6 million, with U.S. sales rising 5% to USD 179.3 million.
• GAAP operating loss narrowed to USD 13.8 million, while GAAP net loss improved to USD 21.2 million.
• Gross margin climbed 460 basis points to 57%, while pump shipments totaled more than 33,000 worldwide, including 22,000 in the U.S.
• Non-GAAP adjusted EBITDA turned positive to USD 6.4 million, with 10% of U.S. sales coming through the pharmacy channel.
• Reaffirmed 2026 sales guidance of about USD 1.065 billion to USD 1.085 billion; highlighted a 510(k) submission for Tandem Mobi tubeless capability.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tandem Diabetes Care Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202608061605BIZWIRE_USPR_____20260806_BW666275) on August 06, 2026, and is solely responsible for the information contained therein.